CELU vs LVTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LVTX Captures Institutional Edge (2โ1 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to LAVA Therapeutics N.V. Ordinary Shares (LVTX) driven by superior Growth & Margin, Momentum & Technical while CELU counters with relative strength in Options & Structure. Fundamentally, CELU trades at N/M Forward P/E with -254.0% operating margin (-5.3% YoY revenue) versus LVTX at N/M Forward P/E and -431.9% operating margin (+1313.6% YoY). In options structure, CELU sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro) against LVTX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CELU | LVTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $15.2M | $45.8M | Larger Scale | LVTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -5.3% | +1313.6% | Higher Growth | LVTX |
| Operating Margin (TTM) Profitability | -254.0% | -431.9% | Higher Margin | CELU |
| Net Profit Margin Profitability | -245.7% | 0.0% | Higher Margin | LVTX |
| Return on Equity (ROE) Capital Efficiency | -6367.2% | -101.5% | Higher ROE | LVTX |
| 52-Week Range Position Momentum | 2% ($0โ$3) | 77% ($1โ$2) | Stronger Trend | LVTX |
| Beta / 30D Volatility Risk Regime | 2.01ฮฒ ยท 135% Vol | -0.02ฮฒ ยท 49% Vol | Lower Realized Risk | LVTX |
| Unified Institutional Score Composite Signal | 42.9 / 100 (HOLD) | 67.0 / 100 (BUY) | Higher Composite | LVTX |